ENOX BIOPHARMA, INC. WILL PRESENT AT IN3 EAST INVESTMENT IN INNOVATION CONFERENCE.
Enox Biopharma, Inc. (VANCOUVER, BC.) CEO, John C. Rewcastle, Ph.D., will present at the IN3 East Investment in Innovation Conference on Wednesday, June 22 at 12:15 AM EST. The conference is being held at the Hyatt Regency Hotel in Boston.
The IN3 East meeting, hosted by Elsevier, is a medtech industry forum and networking meeting. The meeting is designed to provide exposure and constructive interaction between emerging medical innovation companies like Enox Biopharma and both venture capitalists and large device manufacturers.
Dr. Rewcastle will present Enox’s technology whose foundation is the patent protected ability to embed nitric oxide into polymers which renders medical devices antimicrobial. He will also review recently filed intellectual property that expands Enox’s technology to cover the wound healing space.
“One of the most significant problems facing the worldwide medical establishment is hospital acquired infections. In the United States alone, these infections drain an estimated $30-45 billion dollars per year. Enox is uniquely positioned to address this problem with its antimicrobial technology which utilizes nitric oxide as the mechanism of action. Nitric oxide is an ideal antimicrobial agent as it is very effective but does not have resistance issues like antibiotics do.”
“The IN3 East Conference represents a great opportunity,” continued Rewcastle. “Enox will be attractive to both the venture capitalists and potential strategic partners in attendance. Our breakthrough technology has the potential of meeting the needs of hospitals worldwide who are currently underserved by existing infection prevention technology. I anticipate a positive response to our presentation and presence at this event.”
About Enox Biopharma, Inc.
Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox’s device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.
For more information, please contact:
John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.